Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies

Kim Hien T. Dao, Jeffrey W. Tyner

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

Original languageEnglish (US)
Pages (from-to)1309-1311
Number of pages3
JournalClinical Cancer Research
Issue number6
StatePublished - Mar 15 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies'. Together they form a unique fingerprint.

Cite this